Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis

Clinical Pharmacology and Therapeutics

Volumn 80, Issue 6, 2006, Pages 597-606

  De Martin, Sara ^a   Orlando, Rocco ^a   Bertoli, Massimo ^a   Pegoraro, Paola ^a   Palatini, Pietro ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALLOPURINOL; AMILORIDE; AMLODIPINE; ATENOLOL; ATORVASTATIN; CANDESARTAN; CANRENONE; CARVEDILOL; CLONIDINE; COLCHICINE; DEETHYLLIDOCAINE; DIGOXIN; DOXAZOSIN; ENALAPRIL; ERYTHROPOIETIN; FUROSEMIDE; GLYCINE XYLIDIDE; HYDROCHLOROTHIAZIDE; INSULIN; LIDOCAINE; MEPIVACAINE; NIFEDIPINE; OMEPRAZOLE; PEFLOXACIN; RAMIPRIL; SIMVASTATIN; TAMSULOSIN; UNINDEXED DRUG; WARFARIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DISEASE SEVERITY; DIZZINESS; DROWSINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG TRANSFORMATION; HEMODIALYSIS; HUMAN; HUMAN CELL; KIDNEY AGENESIS; LIVER MICROSOME; LONG TERM CARE; MALE; PARESTHESIA; PLASMA; PRIORITY JOURNAL; STEADY STATE;

AREA UNDER CURVE; BIOTRANSFORMATION; HALF-LIFE; HUMANS; KIDNEY FAILURE, CHRONIC; LIDOCAINE; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; RENAL DIALYSIS;

EID: 33845440807     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1016/j.clpt.2006.08.020     Document Type: Article

References (37)

1. Elston A.C., Bayliss M.K., and Park G.R. Effect of renal failure on drug metabolism by the liver. Br J Anaesth 71 (1993) 282-290
2. Pichette V., and Leblond F.A. Drug metabolism in chronic renal failure. Curr Drug Metab 4 (2003) 91-103
3. Nolin T.D., Frye R.F., and Matzke G.R. Hepatic drug metabolism and transport in patients with kidney disease. Am J Kidney Dis 42 (2003) 906-925
4. Sun H., Frassetto L., and Benet L.Z. Effects of renal failure on drug transport and metabolism. Pharmacol Ther 109 (2006) 1-11
5. Talbert R.L. Drug dosing in renal insufficiency. J Clin Pharmacol 34 (1994) 99-110
6. Cantu T.G., Ellerbeck E.F., Yun S.W., Castine S.D., and Kornhauser D.M. Drug prescribing for patients with changing renal function. Am J Hosp Pharm 49 (1992) 2944-2948
7. Orlando R., Piccoli P., De Martin S., Padrini R., and Palatini P. Effect of the CYP3A4 inhibitor erythromycin on the pharmacokinetics of lignocaine and its pharmacologically active metabolites in subjects with normal and impaired liver function. Br J Clin Pharmacol 55 (2003) 86-93
8. Orlando R., Piccoli P., De Martin S., Padrini R., Floreani M., and Palatini P. Cytochrome P450 1A2 is a major determinant of lidocaine metabolism in vivo: effects of liver function. Clin Pharmacol Ther 75 (2004) 80-88
9. Thompson P.D., and Melmon K.L. Lignocaine pharmacokinetics in advanced heart failure, liver disease and renal failure in humans. Ann Intern Med 78 (1973) 499-508
10. Collinsworth K.A., Strong J.M., Atkinson Jr. A.J., Winkle R.A., Perlroth F., and Harrison D.C. Pharmacokinetics and metabolism of lidocaine in patients with renal failure. Clin Pharmacol Ther 18 (1975) 59-64
11. Ahmed J.H., Grant A.C., Rodger R.S., Murray G.R., and Elliott H.L. Inhibitory effect of uraemia on the hepatic clearance and metabolism of nicardipine. Br J Clin Pharmacol 32 (1991) 57-62
12. DuBois D., and DuBois E.F. A formula to estimate the approximate surface area if height and weight are known. Arch Intern Med 17 (1916) 863-871
13. Segel I.H. Enzyme kinetics. Chap. 2 (1975), John Wiley & Sons, New York 18-99
14. O'Neal C.L., and Poklis A. Sensitive HPLC for simultaneous quantification of lidocaine and its metabolites monoethylglycinexylidide and glycinexylidide in serum. Clin Chem 42 (1996) 330-331
15. Wang J.S., Backman J.T., Wen X., Taavistainen P., Neuvonen P.J., and Kivistö K.T. Fluvoxamine is a more potent inhibitor of lidocaine metabolism than ketoconazole and erythromycin in vitro. Pharmacol Toxicol 85 (1999) 201-205
16. Wagner J.G. Linear pharmacokinetic equations allowing direct calculation of many needed parameters from the coefficients and exponents of polyexponential equations which have been fitted to the data. J Pharmacokinet Biopharm 4 (1976) 443-467
17. i in a competitive enzyme-inhibition model: comparisons among three methods of data analysis. Drug Metab Dispos 27 (1999) 756-762
18. Landi M.T., Sinha R., Lang N.P., and Kadlubar F.F. Human cytochrome P450 1A2. IARC Sci Publ 148 (1999) 173-195
19. Thummel K.E., and Wilkinson G.R. In vitro and in vivo drug interactions involving human CYP 3A. Annu Rev Pharmacol Toxicol 38 (1988) 389-430
20. Dilger K., Zheng Z., and Klotz U. Lack of drug interaction between omeprazole, lansoprazole, pantoprazole and theophylline. Br J Clin Pharmacol 48 (1999) 438-444
21. Parker R.J., Collins J.M., and Strong J.M. Identification of 2,6-xylidine as a major lidocaine metabolite in human liver slices. Drug Metab Dispos 24 (1996) 1167-1173
22. Rowland M., and Tozer T.M. Clinical pharmacokinetics: concepts and applications. Chap. 5 (1995), Williams & Wilkins, Baltimore 53-65
23. Pieper J.A., and Lima H. Lidocaine. Chap. 21. In: Evans W.E., Schentag J.J., and Jusko W.J. (Eds). Applied pharmacokinetics. Principles of therapeutic drug monitoring. 3rd ed. (1992), Applied Therapeutics, Vancouver (WA)
24. Grossman S.H., Davis D., Kitchell B.B., Shand D.G., and Routledge P.A. Diazepam and lidocaine plasma protein binding in renal disease. Clin Pharmacol Ther 31 (1982) 350-357
25. Balant L.P. Renal insufficiency and drug metabolism [in French]. Therapie 42 (1987) 393-397
26. Oellerich M., Schütz E., Polzien F., Ringe B., Armstrong V.W., Hartmann H., et al. Influence of gender on the monoethylglycinexylidide test in normal subjects and liver donors. Ther Drug Monit 16 (1994) 225-231
27. Thomson A.H., Elliot H.L., Kelman A.W., Meredith P.A., and Whiting B. The pharmacokinetics and pharmacodynamics of lignocaine and MEGX in healthy subjects. J Pharmacokinet Biopharm 15 (1987) 101-115
28. Bjornsson T.D., Callaghan J.T., Einolf H.J., Fischer V., Gan L., Grimm S., et al. The conduct of in vitro and in vivo drug-drug interaction study: a pharmaceutical research and manufacturers of America (PhRMA) perspective. Drug Metab Dispos 31 (2003) 815-832
29. Yao C., Kunze K.L., Kharasch E.D., Wang Y., Trager W.F., Ragueneau I., et al. Fluvoxamine-theophylline interactions: gap between in vitro and in vivo inhibition constants toward cytochrome P4501A2. Clin Pharmacol Ther 70 (2001) 415-424
30. Ankemann T., Osterkamp U., Santos S.R., and Kirch W. Elimination and hemodynamic effects of nitrendipine in patients with chronic renal failure. Eur J Clin Pharmacol 36 (1989) 433-437
31. van Bortel L., Bohm R., Mooy J., Schiffers P., and Rahn K.H. Pharmacokinetics of nitrendipine in terminal renal failure. Eur J Clin Pharmacol 36 (1989) 467-471
32. Taburet A.M., Vincent I., Perello L., Coret B., Baune B., and Furlan V. Impairment of drug biotransformation in renal disease; an in vitro model [abstract]. Clin Pharmacol Ther 59 (1996) 136
33. Leblond F.A., Giroux L., Villeneuve J.P., and Pichette V. Decreased in vivo metabolism of drugs in chronic renal failure. Drug Metab Dispos 28 (2000) 1317-1320
34. Leblond F.A., Guevin C., Demers C., Pellerin I., Gascon-Barre M., and Pichette V. Downregulation of hepatic cytochrome P450 in chronic renal failure. J Am Soc Nephrol 12 (2001) 326-332
35. Michaud J., Dubé P., Naud J., Leblond F.A., Desbiens K., Bonnardeaux A., et al. Effect of serum from patients with chronic renal failure on rat hepatic cytochrome P450. Br J Pharmacol 144 (2005) 1067-1077
36. Anttila M., Sotaniemi E.A., Pelkonen O., and Rautio A. Marked effect of liver and kidney function on the pharmacokinetics of selegiline. Clin Pharmacol Ther 77 (2005) 54-62
37. Jerling M., and Abdallah H. Effect of renal impairment on multiple-dose pharmacokinetics of extended-release ranolazine. Clin Pharmacol Ther 78 (2005) 288-297